Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors
Investigation of maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992
Neoplasms
DRUG: BIBW 2992
Maximum tolerated dose (MTD) of BIBW 2992, up to 168 days|Incidence and intensity of Adverse Events according to Common Terminology Criteria (CTC version 3), up to 23 months
Area under the plasma concentration-time curve (AUC) for several time points, up to 28 days|Predose plasma concentration, Predose on day 8, 15, 22 and 27|Plasma concentration at 24 h following the first (C24,1) and the Day 27 dose (C24,27), 24 hours after drug administration on day 24 and 27|Plasma concentration at 3 h following the first dose (C3,1), 3 hours after the first dose on day 1|Maximum measured plasma concentration at steady state on Day 27 (Cmax,ss), up to 24 hours after drug administration on day 27|Time from dosing to the maximum plasma concentration at steady state on Day 27 (tmax,ss), up to 24 hours after drug administration on day 27|Terminal half-life at steady state (t1/2,ss), up to 28 days|Mean residence time after oral administration at steady state (MRTpo,ss), up to 28 days|Apparent clearance at steady state (CL/F,ss), up to 28 days|Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss), up to 28 days|Objective tumor responses, up to 23 months|Correlation of EGFR (epidermal growth factor receptor), HER2, estrogen receptor (ER) and progesterone receptor (PrR) immunohistochemical status as based on tumor biopsies, or excisions obtained prior to this trial, with objective tumor responses, up to 23 months
Investigation of maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992